Acadia Pharmaceuticals | ACAD - Ebitda


Acadia Pharmaceuticals reported $35.76M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
ALKERMES USD 121.55M 4.99M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -5.26M 300.71M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Corcept Therapeutics USD 10.7M 16.45M Sep/2025
Cytokinetics USD -277.18M 169.36M Sep/2025
Eisai JPY 30.1B 6.62B Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Incyte USD 414.5M 92.42M Dec/2025
J&J USD 9.52B 389M Sep/2025
Moderna USD -790M 582M Dec/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Prothena USD -39.53M 12.25M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025